Marktanalyse - Progressive Supranuclear Palsy - Pipeline Review, H2 2016

Global Markets Direct
12.2016
77 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Progressive Supranuclear Palsy - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy — Pipeline Review, H2 2016, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Progressive Supranuclear Palsy Overview 7

Therapeutics Development 8

Pipeline Products for Progressive Supranuclear Palsy - Overview 8

Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 9

Progressive Supranuclear Palsy - Therapeutics under Development by Companies 10

Progressive Supranuclear Palsy - Therapeutics under Investigation by Universities/Institutes 11

Progressive Supranuclear Palsy - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Progressive Supranuclear Palsy - Products under Development by Companies 15

Progressive Supranuclear Palsy - Products under Investigation by Universities/Institutes 16

Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 17

AB Science SA 17

AbbVie Inc 18

AlzProtect SAS 19

Asceneuron SA 20

Bristol-Myers Squibb Company 21

Cortice Biosciences Inc 22

Intellect Neurosciences Inc 23

Prana Biotechnology Ltd 24

Sellas Inc 25

TauRx Therapeutics Ltd 26

Progressive Supranuclear Palsy - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

ABBV-8E12 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ASN-561 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AZP-2006 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BMS-986168 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

DC-TAB - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

DPC-016 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

masitinib - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

MK-8719 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

PBT-434 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

TauC-3 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

tolfenamic acid - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

TPI-287 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

TRx-0237 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

zolpidem tartrate - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Progressive Supranuclear Palsy - Dormant Projects 71

Progressive Supranuclear Palsy - Product Development Milestones 72

Featured News & Press Releases 72

Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy 72

Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 72

Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 73

Dec 10, 2013: Potential Treatment for Parkinson’s & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 73

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77





List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2016 8

Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Progressive Supranuclear Palsy - Pipeline by AB Science SA, H2 2016 17

Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H2 2016 18

Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2016 19

Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H2 2016 20

Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H2 2016 21

Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H2 2016 22

Progressive Supranuclear Palsy - Pipeline by Intellect Neurosciences Inc, H2 2016 23

Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Ltd, H2 2016 24

Progressive Supranuclear Palsy - Pipeline by Sellas Inc, H2 2016 25

Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Progressive Supranuclear Palsy - Dormant Projects, H2 2016 71





List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, H2 2016 8

Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus